From: Kinetic Targeting of pegylated liposomal Doxorubicin: a new Approach to Reduce Toxicity during Chemotherapy (CARL-trial)
n
12
Age (median and range)
53 (39-67)
Staging
IIA
2
IIB
4
IIIA
IIIB
Receptor
ER/PR +/+
ER/PR +/-
6
ER/PR-/-
HER2/neu +